Course Description and Assignments
Immunotherapy has revolutionized cancer treatments. It has resulted in complete and durable responses in several malignancies including advanced melanoma and non-small cell lung cancer, among others. However, responses remain heterogeneous among patients, and some experience serious side effects. In this nanocourse, we will discuss the two major types of cancer immunotherapy: checkpoint blockade and engineered T cells. We will discuss the mechanisms of action, the clinical challenges, and potential approaches to further advance the field.
Each of the four sessions will conclude with a ~20-30 min question and discussion, and a brief homework assignment.
This course is limited to 15 participants.
Session Dates and Times
Priority will be given to graduate students taking the course for credit. In order to receive credit, students must attend all sessions and participate in the discussions. Grades will be assessed based on discussions and homework assignments. Postdocs can register too, however, they will be granted access to the course as space allows.
First session – Monday November 9, 4-5:30 pm, Zoom
Second session – Thursday November 12, 4-5:30 pm, Zoom
Engineered T Cells
Third session – Monday November 16, 4-5:30pm, Zoom
Fourth session – Thursday November 19, 4-5:30pm, Zoom
Mohammad Rashidian & Caron Jacobson
Mohammad Rashidian, PhD
Mohammad Rashidian PhD, Dana-Farber Cancer Institute
Caron Jacobson MD, Medical Director of the Immune Effector Cell Therapy program at Dana-Farber/Brigham and Women's Cancer Center
Jelena Patrnogic, PhD (email@example.com)
|Nanocourse: Cancer Immunotherapy Flyer||0 bytes|